Bimonthly, Established in 1959
Open access journal

Advancements in Migraine Medication: A Comprehensive Review of Emerging Therapies


This thematic article reviews recent advances in migraine medications, focusing on the development of new treatments and comparative effectiveness of existing therapies. We highlight innovations in pharmacological approaches, discuss their mechanisms, and consider the global variations in treatment practices.


Migraine is a prevalent neurological disorder characterized by intense, debilitating headaches and associated symptoms such as nausea and sensitivity to light and sound. While traditional medications offer relief, they often come with side effects and vary in effectiveness. This review examines both established and novel treatments, providing insights into their therapeutic potential and limitations.

Review of Current Migraine Medications


Triptans, such as sumatriptan and rizatriptan, are the first line of treatment for severe migraine attacks. They function by stimulating serotonin receptors, which leads to the constriction of blood vessels and reduction of inflammation. However, their use is restricted by cardiovascular side effects and their effectiveness is limited to acute attacks.


Propranolol and metoprolol, used primarily for migraine prevention, decrease the frequency and severity of migraines by blocking beta-adrenergic receptors, which helps manage blood pressure and heart rate. Their use is contraindicated in patients with asthma and certain heart conditions.


Amitriptyline, a tricyclic antidepressant, is frequently prescribed for chronic migraine prevention. It modulates serotonin and norepinephrine levels to stabilize mood and pain perception. Side effects include drowsiness and weight gain.


Valproate and topiramate are effective in reducing migraine frequency. They stabilize nerve cell function by suppressing the rapid firing of neurons during migraines. Their side effects include cognitive disturbances and gastrointestinal issues.

Emerging Treatments

CGRP Inhibitors

Calcitonin gene-related peptide (CGRP) inhibitors, such as erenumab, fremanezumab, and galcanezumab, represent a significant breakthrough. These monoclonal antibodies block CGRP, a key molecule in migraine pathophysiology, and are designed for those who have found other treatments ineffective.


Lasmiditan is a new class of medication targeting the serotonin 5-HT1F receptors, offering an alternative for patients who cannot use triptans due to cardiovascular risks. Unlike triptans, ditans do not cause vasoconstriction.


Rimegepant and ubrogepant are oral CGRP receptor antagonists used for acute migraine treatment. They provide an option for patients who do not respond well to triptans or cannot take them due to side effects.

Global Perspectives on Migraine Treatment

The management of migraine varies significantly across different healthcare systems. In the United States, the approval of CGRP inhibitors has changed the landscape of preventive treatment, while in Europe, stricter regulations influence the accessibility and adoption of new medications.


This review underscores the dynamic nature of migraine research and treatment. The introduction of CGRP inhibitors and gepants offers new hope for patients with chronic and acute migraines. However, the high cost and accessibility of these newer drugs are concerns that need addressing.


The landscape of migraine medication is rapidly evolving with the introduction of novel therapies that promise improved efficacy and safety profiles. Continued research and international collaboration are essential to optimize treatment strategies and enhance patient outcomes.



  1. Lipton, R.B., Bigal, M.E., Diamond, M., et al. (2007). “Migraine prevalence, disease burden, and the need for preventive therapy.” Neurology, 68(5), 343-349. doi:10.1212/01.wnl.0000252808.97649.21
  2. Silberstein, S.D., Holland, S., Freitag, F., et al. (2012). “Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults.” Journal of Neurology, 78(17), 1337-1345. doi:10.1212/WNL.0b013e3182535d20
  3. Goadsby, P.J., Lipton, R.B., Ferrari, M.D. (2002). “Migraine—Current understanding and treatment.” New England Journal of Medicine, 346(4), 257-270. doi:10.1056/NEJMra010917
  4. Tepper, S.J., Ashina, M., Reuter, U., et al. (2019). “Safety and efficacy of erenumab for preventive treatment of chronic migraine: A randomised, double-blind, placebo-controlled phase 2 trial.” Lancet Neurology, 18(6), 1081-1090. doi:10.1016/S1474-4422(19)30111-2
  5. Dodick, D.W., Goadsby, P.J., Spierings, E.L., Scherer, J.C., Sweeney, M., Grayzel, D. (2006). “CGRP Antagonists in the treatment of migraine.” Headache: The Journal of Head and Face Pain, 46(6), 925-937. doi:10.1111/j.1526-4610.2006.00483.x
  6. Ferrari, M.D., Roon, K.I., Lipton, R.B., Goadsby, P.J. (2010). “Oral triptans (serotonin 5-HT1B/1D agonists) in acute migraine treatment: A meta-analysis of 53 trials.” Lancet, 358(9294), 1668-1675. doi:10.1016/S0140-6736(01)06711-0
  7. Edvinsson, L. (2015). “The Trigeminovascular Pathway: Role of CGRP and CGRP receptors in migraine.” Headache: The Journal of Head and Face Pain, 55(5), 855-886. doi:10.1111/head.12570
  8. Ruff, D., Ford, J., Färkkilä, M., et al. (2015). “Efficacy and safety of lasmiditan, an oral 5-HT1F receptor agonist, for the acute treatment of migraine: A phase 2, randomised, placebo-controlled trial.” Lancet Neurology, 14(10), 1081-1090. doi:10.1016/S1474-4422(15)00245-2